PTH suppression by calcitriol does not predict off-target actions in experimental CKD

Area of Science:

• Nephrology and Endocrinology
• Cardiovascular Health in Chronic Kidney Disease

Background:

• Vitamin D receptor agonist (VDRA) therapy is standard for managing hyperparathyroidism in severe chronic kidney disease (CKD).
• Calcitriol (1,25-(OH)2D3), a VDRA, was a primary treatment but is linked to accelerated vascular calcification (VC) in CKD patients.

Purpose of the Study:

• To investigate if modifying calcitriol delivery profiles in an experimental CKD model can improve vascular health outcomes.
• To assess the relationship between different levels of parathyroid hormone (PTH) suppression and CKD-related morbidities.

Main Methods:

• Experimental CKD was induced in rats using a high adenine diet.
• Rats received varied calcitriol dosing strategies (single dose vs. four times daily) at different concentrations.
• Key markers including arterial calcium and phosphate, circulating calcium, phosphate, PTH, FGF-23, VWF, and vitamin D metabolites were measured.

Main Results:

• Calcitriol treatment led to dose-dependent PTH suppression initially, but this effect diminished over time.
• Vascular calcification and circulating FGF-23 and VWF levels significantly increased across all calcitriol treatment groups.
• No significant differences in negative CKD outcomes were observed based on the level of PTH suppression achieved.

Conclusions:

• PTH suppression level is an inadequate indicator of overall treatment efficacy for CKD morbidity.
• A comprehensive evaluation beyond PTH suppression is necessary for assessing CKD treatment effectiveness.
• Further research into alternative VDRA therapies for CKD management is warranted.